Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: A multicenter study
Article first published online: 29 JUL 2014
© 2014 The Authors. Psychiatry and Clinical Neurosciences © 2014 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences
Special Issue: Conquering depression
Volume 69, Issue 1, pages 43–48, January 2015
How to Cite
Jung, W.-Y., Kim, S.-G., Lee, J.-S., Kang, D.-H., Jung, B.-J., Shin, D.-H., Lee, Y.-M. and Choi, S.-H. (2015), Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: A multicenter study. Psychiatry and Clinical Neurosciences, 69: 43–48. doi: 10.1111/pcn.12212
- Issue published online: 4 JAN 2015
- Article first published online: 29 JUL 2014
- Accepted manuscript online: 6 JUN 2014 03:01AM EST
- Manuscript Accepted: 2 JUN 2014
- Manuscript Revised: 1 MAY 2014
- Manuscript Received: 10 FEB 2014
- Pfizer Pharmaceuticals Korea
- depressive symptom;
The goal of this study was to examine the efficacy and safety of ziprasidone to treat depressive symptoms in Korean patients with schizophrenia who showed stable symptoms.
In this 8-week, open-label, prospective, non-randomized, multicenter study, 34 patients with schizophrenia who showed a stable response to previous medications, maintained a stable dose, and who had depressive symptoms, were recruited. Ziprasidone was the only antipsychotic agent allowed for 8 weeks after a 2–7-week washout period.
Steady decreases were observed on the Montgomery–Asberg Depression Rating Scale, the Calgary Depression Scale for Schizophrenia, the Positive and Negative Syndrome Scale, and the Clinical Global Impression-Severity Scale scores. The Montgomery–Asberg Depression Rating Scale score was 20.26 ± 4.77 at baseline and 12.21 ± 7.94 at the end-point (P < 0.01). The Calgary Depression Scale for Schizophrenia score was 9.76 ± 4.11 at baseline and 5.00 ± 3.94 at the end-point (P < 0.01). The Positive and Negative Syndrome Scale total score was 75.24 ± 22.63 at baseline and 66.53 ± 24.28 at the end-point (P < 0.01). The Clinical Global Impression-Severity Scale score was 3.44 ± 0.66 at baseline and 3.15 ± 0.86 at the end-point (P < 0.05). No significant differences were observed for total scores on the Simpson and Angus Rating Scale, the Barnes Akathisia Rating Scale, or the Abnormal Involuntary Movement Scale between the baseline and end-point.
Ziprasidone was effective for improving depressive symptom scores and was well tolerated. Switching to ziprasidone is a good strategy in patients with schizophrenia who are experiencing depressive symptoms.